Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

ClinicalTrials.gov ID: NCT06388564

Public ClinicalTrials.gov record NCT06388564. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

Study identification

NCT ID
NCT06388564
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
130 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 10, 2024
Primary completion
May 31, 2027
Completion
Nov 30, 2029
Last update posted
May 21, 2026

2024 – 2029

United States locations

U.S. sites
25
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
Mayo Clinic Hospital Phoenix Arizona 85054
City of Hope Medical Center Duarte California 91010
University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic Los Angeles California 90095
Stanford Cancer Center Stanford California 94305
University of Colorado Cancer Center Aurora Colorado 80045
Colorado Blood Cancer Institute Denver Colorado 80218
Smilow Cancer Center-Yale New Haven Connecticut 06510
Mayo Clinic Jacksonville Jacksonville Florida 32224
Northwestern University Chicago Illinois 60611
The University of Chicago Medicine Chicago Illinois 60637
University of Maryland-Greenebaum Cancer Center Baltimore Maryland 21201
Washington University St Louis Missouri 63110
Fred and Pamela Buffett Cancer Center Omaha Nebraska 68198
Memorial Sloan Kettering Cancer Center New York New York 10021
Weill Cornell Medicine New York New York 10021
Mount Sinai Hospital New York New York 10029
Cleveland Clinic Cleveland Ohio 44195
The Ohio State University Columbus Ohio 43210
University of Pennsylvania Abramson Cancer Center Philadelphia Pennsylvania 19104
Hillman Cancer Center Pittsburgh Pennsylvania 15232
Vanderbilt University Medical Center Nashville Tennessee 37232
Md Anderson Cancer Center Houston Texas 77030
Fred Hutchinson Cancer Center Seattle Washington 98109
University of Washington Seattle Washington 98195
Froedtert & the Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06388564, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 21, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06388564 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →